{
    "root": "341a3d04-770f-72c1-e063-6294a90a1287",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "topiramate",
    "value": "20250501",
    "ingredients": [
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLYETHYLENE GLYCOL 6000",
            "code": "30IQX730WE"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TOPIRAMATE",
            "code": "0H73WJJ391"
        }
    ],
    "indications": "Topiramate tablets are indicated for: Epilepsy: initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older (1.1); adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older ( 1.2 ) Preventive treatment of migraine in patients 12 years of age and older ( 1.3 )",
    "contraindications": "Topiramate tablets initial dose, titration, and recommended maintenance dose varies by indication and age group. See Full Prescribing Information for recommended dosage, and dosing considerations in patients with renal impairment, geriatric patients, and patients undergoing hemodialysis ( 2.1 , 2.2 , 2.3 , 2.4 , 2.5 , 2.6 )",
    "warningsAndPrecautions": "200 mg Tablet:\n                  Yellow, round, bevel edged, biconvex, film-coated tablets with 'U' debossed on one side and '118' debossed on other side.\n                  \n                     NDC 72162-2483-6: 60 Tablets in a BOTTLE\n                     NDC 72162-2483-5: 500 Tablets in a BOTTLE\n                     NDC 72162-2483-0: 1000 Tablets in a BOTTLE\n                  \n                  \n                  Store at 20째 to 25째C (68째 to 77째F) [see USP Controlled Room Temperature]. Protect from moisture.\n                  Dispense in a tight, light-resistant container.\n                  \n                  Repackaged/Relabeled by:\n  \nBryant Ranch Prepack, Inc.\n  \nBurbank, CA 91504",
    "adverseReactions": "None."
}